Endo, Inc.

OTCPK:ENDP.Q Stock Report

Market Cap: US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Management

Management criteria checks 3/4

Endo International's CEO is Blaise Coleman, appointed in Dec 2016, has a tenure of 7.42 years. total yearly compensation is $12.85M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $253.23. The average tenure of the management team and the board of directors is 4.8 years and 7 years respectively.

Key information

Blaise Coleman

Chief executive officer

US$12.8m

Total compensation

CEO salary percentage7.61%
CEO tenure7.4yrs
CEO ownership0.2%
Management average tenure4.8yrs
Board average tenure7yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 16

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Endo International (NASDAQ:ENDP) creditors are looking at putting the pharma company up for sale through a bankruptcy, likely through a Chapter 11 filing in New York, Bloomberg reported. Endo (ENDP) has a debt load of more than $8B and is still facing many lawsuits over its alleged role in the nation's opioid epidemic. A bankruptcy filing would make it easier for Endo (ENDP) to make deals with with governments and other entities suing the company. Bloomberg said that some first-lien lenders are competing to use their debt holdings toward a bid for the company’s assets. Seeking Alpha contributor CashFlow Hunter, which has a strong sell rating on Endo (ENDP), has said a bankruptcy filing is imminent.
Seeking Alpha • Aug 03

Endo International sees 23% rise on 3x higher than normal volume

Shares of Endo International (NASDAQ:ENDP) have risen sharply and are up 23% Wednesday afternoon amid three times higher than usual daily volume. The drugmaker's average daily volume is ~46.2M shares. As of 215p ET, more than 138M shares had traded hands. Endo (ENDP) is also having unusual options trading volume that is six times the daily normal. Seeking Alpha contributor CashFlow Hunter says the company is a strong sell with a bankruptcy filing likely.
Seeking Alpha • Jul 25

Endo outperforms defying bankruptcy fears and generic entry

The shares of Endo International (NASDAQ:ENDP) rose sharply on Monday even as the company continues to grapple with concerns over the generic threat to a key drug, failure to fulfill debt commitments, and potential bankruptcy filing amid ongoing opioid litigation. Despite an ~89% YTD decline, Endo (ENDP) has added ~13% over the past 30 days outperforming the broader market, as shown in this graph. The upsurge comes despite a recent WSJ report on the company’s plan to file for Chapter 11 bankruptcy without striking a settlement on thousands of opioid claims. In June, Dublin, Ireland-based Endo (ENDP) opted to skip interest payments owed to its junior bondholders citing the ongoing talks with certain creditors regarding its decision to evaluate strategic alternatives. A decline in earnings, driven in part by the loss of exclusivity for its leading sales generator, Vasostrict, has exacerbated the operational issues. In May, Piper Sandler downgraded Endo (ENDP), noting the generic competition to the vasopressin injection, which added $155.9M to the company topline in 1Q 2022 with ~30% YoY decline.
Seeking Alpha • Jul 12

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International (NASDAQ:ENDP) shares plunged ~20% Tuesday after The Wall Street Journal reported that the generic drugmaker is advancing towards a bankruptcy filing without reaching a settlement on opioid claims against the company. According to people familiar with the matter, despite years of negotiations with opioid claimants, Endo (ENDP) is weighing chapter 11 bankruptcy to restructure its over $8B debt and thousands of ongoing litigations. Endo (ENDP) has been negotiating with a group of senior creditors after the company missed interest payments to junior bondholders last month, the people said, adding that the management expects to reach a deal with them before a near-term bankruptcy process starts. However, a bankruptcy filing is unlikely if the company inks agreements with junior bondholders and opioid plaintiffs, the people said, noting that the situation could change. Endo (ENDP) declined to comment. Read: “Bankruptcy filing should be imminent” for Endo (ENDP), Seeking Alpha contributor CashFlow Hunter predicted in May.
Seeking Alpha • Jun 29

Endo International cools off, giving back some of its 85% Tuesday gain

Shares of Endo International are down 24% in Wednesday afternoon trading, a day after the pharma closed up 85%. The reason for Tuesday's surge was a news release issued by law firm White & Case on behalf of a group of institutional investors holding unsecured notes in Endo (NASDAQ:ENDP) subsidiaries. The group has proposed that the company commence a cash tender offer or commence a debt-for-debt exchange. Also, it is against a near-term bankruptcy filing as Endo (ENDP) has strong liquidity and it "could destroy significant value for stakeholders." Endo (ENDP) has been struggling as a result of multi-million-dollar settlements in state opioid crisis cases.
Seeking Alpha • May 10

Endo: Stick A Fork In It

Second quarter guidance implies catastrophic sales and margins from Vasostrict. Bonds plummeted implying first lien debt might be impaired. Possibly impairment of first lien debt and near certain impairment of second lien debt means zero equity value. Bankruptcy filing should be imminent.
Seeking Alpha • Mar 07

Endo: About As Bad As It Gets

Entrance of generic competitor to Vasostrict materially hurting revenue. QWO uptake seems slow with concerns around discoloration side-effect. Q1 guide implies leverage rising dangerous levels. Bankruptcy seems like an increasingly likely option.
Seeking Alpha • Dec 16

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 million of high margin sales last year. Eagle expects 180-day marketing exclusivity for vasopressin. Continue to see the stock as high risk.
Seeking Alpha • Nov 02

Endo: A Win In California But Equity Value Still A Question

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. Leverage remains too high, particularly with Vasostrict EBITDA at risk. Bankruptcy is now likely off the table but struggle to see equity value.
Seeking Alpha • Aug 31

Endo International: Loses Vasostrict Trial

Judge rules Eagle Pharmaceuticals' version of the drug does not infringe on two patents held by Par Pharmaceuticals, the unit that produces vasostrict. Expect Eagle to start producing and marketing a generic form of vasostrict to treat low blood pressure in the next few months. Approximately 30% of Endo Pharmaceuticals' revenue and EBITDA will take a hit. The loss likely wipes out any equity value for Endo and impairs unsecured bonds.
Seeking Alpha • Aug 20

Endo International: Hires Restructuring Advisor

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing.
Seeking Alpha • Aug 07

Endo International: All About Ongoing Litigation

Company settled with the eastern TN counties for $35mm but do the economics make any sense? NY litigation is ongoing with plaintiffs seeking default liability judgment on the same grounds as TN. Vasostrict trial with Eagle Pharmaceuticals is ongoing. >25% of EBITDA at risk. Quarter operationally solid, but questions remain on market acceptance of QWO.
Seeking Alpha • Jul 15

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

The denied request is likely the last chance to stop the Tennessee damages trial set to begin on July 26. The company already has a default judgment against it. The company could face a $2.4 billion judgment leveled against it. Appeal denial is one more piece pointing to likely bankruptcy filing.
Seeking Alpha • Jun 30

Endo International: Bankruptcy Seems Like The Only Practical Option

A Tennessee state court issued a "default judgement" in April against the company in the lawsuit by county prosecutors over the company's generic for oxycontin, Opana. Earlier this month, a Tennessee appellate court declined to review that default judgement. The damages trial begins on July 26 in Tennessee. Plaintiffs are seeking $2.4 billion. A trial for a suit against the company begins in New York on June 28th and a California trial is ongoing. A bankruptcy filing is very likely the only way to settle all of these cases in a manner that preserves value.

CEO Compensation Analysis

How has Blaise Coleman's remuneration changed compared to Endo International's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$2b

Sep 30 2023n/an/a

-US$252m

Jun 30 2023n/an/a

-US$942m

Mar 31 2023n/an/a

-US$3b

Dec 31 2022US$13mUS$978k

-US$3b

Sep 30 2022n/an/a

-US$3b

Jun 30 2022n/an/a

-US$3b

Mar 31 2022n/an/a

-US$681m

Dec 31 2021US$29mUS$913k

-US$569m

Sep 30 2021n/an/a

US$129m

Jun 30 2021n/an/a

US$109m

Mar 31 2021n/an/a

US$137m

Dec 31 2020US$7mUS$829k

US$247m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$75m

Mar 31 2020n/an/a

-US$190m

Dec 31 2019US$4mUS$612k

-US$361m

Sep 30 2019n/an/a

-US$418m

Jun 30 2019n/an/a

-US$522m

Mar 31 2019n/an/a

-US$477m

Dec 31 2018US$3mUS$569k

-US$962m

Sep 30 2018n/an/a

-US$968m

Jun 30 2018n/an/a

-US$921m

Mar 31 2018n/an/a

-US$2b

Dec 31 2017US$4mUS$546k

-US$1b

Compensation vs Market: Blaise's total compensation ($USD12.85M) is above average for companies of similar size in the US market ($USD674.46K).

Compensation vs Earnings: Blaise's compensation has been consistent with company performance over the past year.

CEO

Blaise Coleman (49 yo)

7.4yrs
Tenure
US$12,849,847
Compensation

Mr. Blaise A. Coleman serves as President, Chief Executive Officer and Director of Endo Inc. Mr. Blaise serves as President, Chief Executive Officer and Director at Endo International plc since March 06, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Blaise Coleman
President7.4yrsUS$12.85m0.18%
$ 253.2
Matthew Maletta
Executive VP9yrsUS$4.25m0.15%
$ 210.7
James Tursi
Executive Vice President of Global Research & Development2.3yrsUS$6.36mno data
Mark Bradley
Executive VP & CFO4.2yrsUS$7.98mno data
Frank Raciti
VP, Controller & Chief Accounting Officerno datano datano data
Cheryl Stouch
Senior VP of Information Technology & Chief Information Officer1.9yrsno datano data
Laure Park
Senior Vice President of Investor Relations & Corporate Affairs5.8yrsno datano data
Susan Williamson
Senior VP & Chief Compliance Officer6.1yrsno datano data
Tracy Basso
Chief Human Resources Officer4.8yrsno datano data
Patrick Barry
Executive VP & President of Global Commercial Operations7.4yrsUS$7.78mno data
James Papp
Head of Endo Ventures Limited & Senior VP of Global Supply Chain3.5yrsno datano data
Michael McGuinness
Global Head of Quality & Compliance1.9yrsno datano data
4.8yrs
Average Tenure
54yo
Average Age

Experienced Management: ENDP.Q's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Blaise Coleman
President4.2yrsUS$12.85m0.18%
$ 253.2
Mark Barberio
Independent Chairman4.3yrsUS$840.00k0.016%
$ 22.9
Michael Hyatt
Independent Director10.3yrsUS$625.00k0.15%
$ 213.3
William Montague
Independent Director10.3yrsUS$625.00k0.042%
$ 59.3
Shane Cooke
Independent Director9.8yrsUS$505.00k0.043%
$ 60.0
Jennifer Chao
Independent Director3.3yrsUS$480.00k0.011%
$ 14.9
Nancy Hutson
Independent Director10.3yrsUS$505.00k0.047%
$ 65.8
Mary Smith
Independent Non-Executive Director3.8yrsUS$480.00k0.014%
$ 19.7
7.0yrs
Average Tenure
61yo
Average Age

Experienced Board: ENDP.Q's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/02 21:42
End of Day Share Price 2024/05/02 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Endo, Inc. is covered by 32 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research